These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 36159398)
1. Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. Qi Z; Long X; Liu J; Cheng P Front Cell Neurosci; 2022; 16():819363. PubMed ID: 36159398 [TBL] [Abstract][Full Text] [Related]
2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932 [TBL] [Abstract][Full Text] [Related]
3. Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity. Qi Z; Zhao J; Li Y; Zhang B; Hu S; Chen Y; Ma J; Shu Y; Wang Y; Cheng P Front Immunol; 2023; 14():982180. PubMed ID: 37114043 [TBL] [Abstract][Full Text] [Related]
4. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. Qiao J; Dey M; Chang AL; Kim JW; Miska J; Ling A; M Nettlebeck D; Han Y; Zhang L; Lesniak MS Oncoimmunology; 2015 Aug; 4(8):e1022302. PubMed ID: 26405578 [TBL] [Abstract][Full Text] [Related]
6. Emerging therapies for glioblastoma: current state and future directions. Rong L; Li N; Zhang Z J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347 [TBL] [Abstract][Full Text] [Related]
7. Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate. Chen Q; Wu J; Ye Q; Ma F; Zhu Q; Wu Y; Shan C; Xie X; Li D; Zhan X; Li C; Li XF; Qin X; Zhao T; Wu H; Shi PY; Man J; Qin CF mBio; 2018 Sep; 9(5):. PubMed ID: 30228241 [TBL] [Abstract][Full Text] [Related]
8. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413 [No Abstract] [Full Text] [Related]
9. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615 [TBL] [Abstract][Full Text] [Related]
10. Virus-Based Immunotherapy of Glioblastoma. Martikainen M; Essand M Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764570 [TBL] [Abstract][Full Text] [Related]
11. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Li M; Li G; Kiyokawa J; Tirmizi Z; Richardson LG; Ning J; Das S; Martuza RL; Stemmer-Rachamimov A; Rabkin SD; Wakimoto H Acta Neuropathol Commun; 2020 Dec; 8(1):221. PubMed ID: 33308315 [TBL] [Abstract][Full Text] [Related]
12. Effects of oncolytic viruses and viral vectors on immunity in glioblastoma. Liu P; Wang Y; Wang Y; Kong Z; Chen W; Li J; Chen W; Tong Y; Ma W; Wang Y Gene Ther; 2022 Apr; 29(3-4):115-126. PubMed ID: 33191399 [TBL] [Abstract][Full Text] [Related]
13. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150 [TBL] [Abstract][Full Text] [Related]
14. Glioblastoma multiforme: novel therapeutic targets. Muir M; Gopakumar S; Traylor J; Lee S; Rao G Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767 [TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viruses for Malignant Glioma: On the Verge of Success? Suryawanshi YR; Schulze AJ Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501 [TBL] [Abstract][Full Text] [Related]
17. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma. Tang L; Zhang M; Liu C Front Immunol; 2022; 13():882257. PubMed ID: 35651605 [TBL] [Abstract][Full Text] [Related]
18. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U Front Immunol; 2020; 11():1402. PubMed ID: 32765498 [TBL] [Abstract][Full Text] [Related]
19. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma. Zhang Q; Zhang J; Tian Y; Wang J; Jin G; Liu F Virology; 2023 Oct; 587():109885. PubMed ID: 37738842 [TBL] [Abstract][Full Text] [Related]
20. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]